What conditions does filgotinib mainly treat?

Filgotinib is an oral selective Janus kinase 1 (JAK1) inhibitor, mainly used to treat autoimmune diseases such as moderately to severely active rheumatoid arthritis (RA), especially for patients who have previously had poor response to traditional DMARDs (disease-modifying anti-rheumatic drugs). The JAK signaling pathway plays a key role in the human immune system. It mediates the signaling of a variety of inflammatory factors and participates in the activation and expansion of immune cells. In autoimmune diseases such as rheumatoid arthritis, this signaling pathway is often overactive, causing the immune system to attack its own tissues, causing joint pain, swelling, and limited function.

The advantage of filgotinib lies in its high selectivity forJAK1. Compared with non-selective JAK inhibitors, it may have better safety while maintaining efficacy. This selective inhibition can reduce interference with other JAK family members (such as JAK2 or JAK3), thereby reducing the risk of certain adverse reactions associated with broad-spectrum JAK inhibition, such as cytopenias and increased risk of infection. In addition to rheumatoid arthritis, filgotinib is also being studied for the treatment of other inflammatory diseases, including ulcerative colitis.

In Europe and some Asian countries, filgotinib has been approved by regulatory agencies for the treatment of moderate to severe rheumatoid arthritis, and has become an important member ofJAK pathway targeted therapies. As the understanding of the mechanisms of immune-related diseases continues to deepen, filgotinib, as a representative drug for precise targeting, may further expand its indications, bringing more treatment options to patients. In clinical use, this drug is usually used in combination with methotrexate (MTX) or as a single drug. The specific treatment plan should be formulated by a rheumatology immunologist based on individual situation assessment.

Reference materials:https://go.drugbank.com/drugs/DB14845